SCHEMBL379749

SCHEMBL379749

Clc1ccccc1-c1nnc2cc(Br)ccn12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 9/20 0.48
ALDH1A1 P00352 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47
LMNA P02545 1/20 0.47
RAB9A P51151 1/20 0.47
PDE2A O00408 1/20 0.45
PDE10A Q9Y233 1/20 0.45
MAPK13 O15264 2/20 0.45
KDM4E B2RXH2 2/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GABRA1 P14867 1/20 0.38
TSHR P16473 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38
ABL1 P00519 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379822 0.84 HSD11B1 (0.50) HSD11B1ALDH1A1SMN1; SMN2NPC1LMNA
SCHEMBL13385743 0.83 HSD11B1 (0.53) HSD11B1ALDH1A1SMN1; SMN2NPC1LMNA
SCHEMBL3623290 0.82 HSD11B1 (0.47) HSD11B1ALDH1A1SMN1; SMN2NPC1LMNA
SCHEMBL380073 0.82 HSD11B1 (0.40) HSD11B1SMN1; SMN2PDE2APDE10AMAPK13
SCHEMBL10288932 0.82 HSD11B1 (0.47) HSD11B1ALDH1A1SMN1; SMN2NPC1LMNA
SCHEMBL4072097 0.77 HSD11B1 (0.49) HSD11B1ALDH1A1SMN1; SMN2NPC1LMNA
SCHEMBL31096117 0.73 AHR (0.36) ALDH1A1SMN1; SMN2KDM4EKMT2AABL1
SCHEMBL10288933 0.71 KDM4E (0.46) HSD11B1ALDH1A1SMN1; SMN2NPC1LMNA
SCHEMBL379692 0.70 HSD11B1 (0.52) HSD11B1LMNAPDE2APDE10AMAPK13
SCHEMBL9987840 0.70 DNMT1 (0.42) ALDH1A1SMN1; SMN2NPC1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2086973-B1 IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF AMGEN INC (US) 2012-01-25 EP disclosed
US-7700593-B2 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2010-04-20 US disclosed
US-7700593-B2 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2010-04-20 US disclosed
US-7700593-B2 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2010-04-20 US disclosed
US-20080161303-A1 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2008-07-03 US disclosed
US-20080161303-A1 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2008-07-03 US disclosed
US-20080161303-A1 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161303-A1 Imidazo- and triazolo-pyridine compounds and methods of use thereof MAPK1, MAP3K1, MAP3K7 HSD11B1 2370/4885ALDH1A1 2024/4885SMN1; SMN2 4659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.